THE LIPOSOME COMPANY's ABELCET (ABLC) GAINS APPROVAL FOR ASPERGILLOSIS IN SIX MONTHS -- FIRM's FIRST DRUG IN THE U.S.; LAUNCH EXPECTED IN JANUARY
Executive Summary
The Liposome Company's amphotericin B lipid complex Abelcet (formerly called ABLC), was approved Nov. 20 by FDA for treatment of patients with the systemic fungal infection aspergillosis who are refractory to or intolerant of conventional amphotericin B therapy. The NDA was submitted May 24 and was given a priority review by FDA in just under six months.